UroVysion Compared with Cytology and Quantitative Cytology in the Surveillance of Non-Muscle-Invasive Bladder Cancer

European Urology

Volumn 51, Issue 5, 2007, Pages 1275-1280

  Moonen, Paula M J ^a   Merkx, Gerard F M ^a   Peelen, Pim ^a   Karthaus, Herbert F M ^b   Smeets, Dominique F C M ^a   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Bladder cancer; FISH; Quanticyt; Quantitative cytology; UroVysion

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER MUSCLE; CANCER INVASION; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; COMPARATIVE STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE PROBE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; URINE CYTOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 9; CYSTOSCOPY; CYTODIAGNOSIS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; URINE;

EID: 33947288413     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.10.044     Document Type: Article

References (20)

1. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
2. Sokolova I.A., Halling K.C., Jenkins R.B., et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2 (2000) 116-123
3. Williams S.G., and Stein J.P. Molecular pathways in bladder cancer. Urol Res 32 (2004) 373-385
4. van der Poel H.G., Witjes J.A., van Stratum P., Boon M.E., Debruyne F.M., and Schalken J.A. Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer. Urology 48 (1996) 357-364
5. van der Poel H.G., Boon M.E., van Stratum P., et al. Conventional bladder wash cytology performed by four experts versus quantitative image analysis. Mod Pathol 10 (1997) 976-982
6. Greene FL, Balch CM, Fleming ID, et al. AJCC cancer staging handbook: TNM classification of malignant tumors. 6th ed, part IX. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Heidelberg: Springer-Verlag; 2002. p. 335-40.
7. World Health Organization. Histological typing of urinary bladder tumours. International histological classification of tumours, no 10. Geneva: World Health Organization; 1973.
8. Halling K.C. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 3 (2003) 507-519
9. van Rhijn B.W., van der Poel H.G., and van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47 (2005) 736-748
10. Sarosdy M.F., Schellhammer P., Bokinsky G., et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168 (2002) 1950-1954
11. Laudadio J., Keane T.E., Reeves H.M., Savage S.J., Hoda R.S., and Lage J.M. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int 96 (2005) 1280-1285
12. Friedrich M.G., Toma M.I., Hellstern A., et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 92 (2003) 911-914
13. Halling K.C., King W., Sokolova I.A., et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 167 (2002) 2001-2006
14. Halling K.C., King W., Sokolova I.A., et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 164 (2000) 1768-1775
15. Skacel M., Fahmy M., Brainard J.A., et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169 (2003) 2101-2105
16. Pycha A., Lodde M., Comploj E., et al. Multicolour-FISH for the risk stratification of superficial bladder cancer. Eur Urol Suppl 5 (2006) 254 (abstract no. 925)
17. Bollmann M., Heller H., Bankfalvi A., Griefingholt H., and Bollmann R. Quantitative molecular urinary cytology by fluorescence in situ hybridization: a tool for tailoring surveillance of patients with superficial bladder cancer?. BJU Int 95 (2005) 1219-1225
18. Kipp B.R., Karnes R.J., Brankley S.M., et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 173 (2005) 401-404
19. Kang J.U., Koo S.H., Jeong T.E., Kwon K.C., Park J.W., and Jeon C.H. Multitarget fluorescence in situ hybridization and melanoma antigen genes analysis in primary bladder carcinoma. Cancer Genet Cytogenet 164 (2006) 32-38
20. Hakenberg O., Schmidt U., Berdjis N., et al. Comparison of urinary cytology and fluorescence-in-situ hybridisation assay (FISH) for the detection of urothelial bladder carcinoma. Eur Urol Suppl 5 (2006) 138 (abstract no. 462)